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Introduction: Neuronatin is a protein that is specifically expressed
in the nervous system in the course of embryonal brain development,
and its expression is limited to the pituitary gland in normal human
adults. Neuronatin expression has been reported in some types of
tumor. The purpose of this study was to clarify the significance of
neuronatin expression in pulmonary non-small cell carcinoma.
Methods:We determined the frequency of neuronatin expression in
surgically resected samples from non-small cell lung carcinoma (51
adenocarcinoma and 41 squamous cell carcinoma) by immunohis-
tochemical staining, and investigated the correlations between ex-
pression level and various clinicopathological features.
Results: Expression of neuronatin was observed more frequently in
squamous cell carcinoma (63%) than in adenocarcinoma (25%). In
most cases, nontumorous lung tissue did not react with the antibody
against neuronatin. In both adenocarcinoma and squamous cell
carcinoma, less differentiated tumors expressed neuronatin more
frequently than did differentiated tumors. In adenocarcinoma, but
not squamous cell carcinoma, the prognosis of neuronatin-positive
cases was significantly worse than that of neuronatin-negative cases.
Conclusion: Neuronatin expression is specific for tumor tissue and
was detected in both pulmonary adenocarcinoma and squamous cell
carcinoma at high frequency, particularly in less differentiated
tumors. Neuronatin expression is associated with poor prognosis in
patients with adenocarcinoma, and may be useful as a prognostic
marker for lung adenocarcinoma.
Key Words: Neuronatin, Non-small cell lung carcinoma, Adeno-
carcinoma, Prognosis, Tumor marker.
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Neuronatin is a protein that is specifically expressed in thenervous system in the course of embryonal brain devel-
opment in mammals. Neuronatin was initially discovered in
rats during a search for genes considered to be important for
development of the central nervous system.1 In the mamma-
lian fetus, neuronatin seems to contribute to the development
and maturation of the hindbrain and pituitary gland. During
later embryogenesis, the neuronatin gene is strongly ex-
pressed in the major part of the central and peripheral nervous
system.2 In human brain, neuronatin mRNA is selectively
expressed during fetal development, but becomes repressed
in adulthood. The deduced neuronatin protein has two distinct
domains, a hydrophobic N-terminal domain and a basic
C-terminal domain, and exhibits homology with members of
the proteolipid class of proteins that function as regulatory
subunits of membrane channels.3 As a result of variable
splicing, neuronatin mRNA exists in two forms, alpha and
beta.4 In addition, neuronatin is known as a paternally ex-
pressed imprinted gene.5
In normal human adults, distinct expression of neur-
onatin is found only in the anterior pituitary gland.6 Never-
theless, mRNA expression of neuronatin has been reported in
pituitary adenoma,6,7 myxoid liposarcoma,8 Wilms’ tumor9
and medulloblastoma10 in humans, as well as in prostatic
cancer with neuroendocrine features11 and thyroid stimulat-
ing hormone-producing tumors12 in mice. Furthermore, high
expression has recently been reported in a tamoxifen-resistant
mammary carcinoma cell line.13
Okubo et al. have reported that neuronatin is more
frequently and highly expressed in large cell neuroendocrine
carcinoma than in small cell carcinoma of the lung.14 The
purpose of this study was to clarify the significance of
neuronatin expression in pulmonary non-small cell carcinoma
by immunohistochemical staining, and to investigate the
usefulness of neuronatin gene expression as a prognostic
marker for these tumors.
MATERIALS AND METHODS
Tissue Specimens and Histologic Typing
Materials used in the present study consisted of surgi-
cally resected primary pulmonary carcinoma specimens from
92 patients, and included 51 adenocarcinomas and 41 squa-
mous cell carcinomas. Lobectomy and mediastinal and pul-
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monary hilar lymph node dissection were performed for all
the cases examined at the University Hospital of Tsukuba
(Ibaraki, Japan). Patients with adenocarcinoma underwent
surgery during the period from September 1997 to August
1999, and those with squamous cell carcinoma from Septem-
ber 1996 to August 1999. In principle, all patients in these
periods were included, but patients with pathologic stage IV
lung carcinoma were excluded (two patients with adenocar-
cinoma). Patients with previous treatment history were also
excluded. The surgically resected specimens were fixed rou-
tinely in 10% formalin and embedded in paraffin for histo-
logical examination. In some cases, fresh frozen specimens
were also preserved for Western blot analysis. Informed
consent was obtained from all patients for specimen collec-
tion. All the cases were classified by pathologic stage accord-
ing to the International System for Staging Lung Cancer.15
Histologic typing was performed according to the 2004 edi-
tion of the World Health Organization classification of lung
tumors.16
Immunohistochemical Staining
For immunohistochemical staining for neuronatin,
2-m sections were cut from 10% formalin-fixed and paraf-
fin-embedded specimens. Sections were selected to show
representative histology and adequate cut surface of the
tumor. The sections were deparaffinized in xylene and rehy-
drated in decreasing concentrations of ethanol. For antigen
retrieval, the sections were placed in citrate buffer (pH 6.0)
and heat-treated in an autoclave at 121°C for 15 minutes.
They were stained with an automatic staining machine (Au-
tostainer plus; Dako Cytomation Co., Ltd., Kyoto, Japan)
using an antineuronatin antibody (polyclonal antibody S-14;
Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of
1:50. A Histofine Simple Stain MAX-PO(G) Kit (Nichirei,
Tokyo, Japan) provided the second antibody and the detec-
tion system. The sections were counterstained with hematox-
ylin. The slides were evaluated by standard light microscopy.
For positive or negative controls, we used specimens that had
been shown to be positive or negative in a previous study by
in situ hybridization (data not shown).14
No tumors diffusely showed positive reaction against
antineuronatin antibody. The positive area in the maximum
cut surface of the tumor was very limited. A tumor was
judged to be positive for neuronatin expression when5% of
the cells in the area concerned were stained immunohisto-
chemically. The specificity of the primary antibody was
confirmed by staining in the absence of primary antibody.
Preparation of Cell Extracts and Western Blot
Analysis
Frozen specimens were sliced into 7-m-thick sections,
and six sections were placed in lysis buffer (50 mM Tris HCl,
pH 6.8, 4% SDS, 6% 2-mercaptoethanol, 10% glycerol). A
micropipette and injector with a 27G needle were used to
macerate the tissue and dissolve proteins, followed by incu-
bation for 30 minutes, maintaining the temperature at 4°C
through all procedures. Next, the homogenate was centri-
fuged at 21000g for 30 minutes at 4°C. The supernatant fluid
was used as the total cell lysate. The cell lysate was boiled at
97°C for 3 minutes and loaded onto gels at 20 l per well.
Electrophoresis was performed at 10 mA per gel. Proteins
were transferred from gels to PVDF membranes with a Trans
Blot Semi-Dry Transfer Cell (BioRad Laboratories, Tokyo,
Japan) at 15 V for 50 minutes. To block nonspecific binding,
the membrane was incubated in 1.5% blocking reagent
(Roche Diagnostics, Basel, Switzerland) for 30 minutes at
room temperature. The subsequent immunostaining was per-
formed with a kit (Enhanced Alkaline Phosphatase Western
Blotting Kit, Goat; Oxford Biomedical Research, Inc., Ox-
ford, MI) according to the manufacturer’s instructions. The
primary antibody (1:100 dilution) was the same product as
used for immunohistochemical staining (polyclonal antibody
S-14; Santa Cruz Biotechnology).
Statistical Analysis
Associations of categorical variables were evaluated
with Fisher’s exact test or the chi-square test. Age was
compared by Student’s t test. Survival curves were calculated
by the Kaplan–Meier method and then compared with the
log–rank test. All statistical calculations were performed with
StatView for Windows version 4.54 (Abacus Concepts,
Berkeley, CA). Differences were considered statistically sig-
nificant if the p value was 0.05.
RESULTS
Patient Background
Of the 51 adenocarcinoma patients, the mean age was
70.0 years (range 37–80 years), and there were 27 male and
24 female patients. The total numbers of patients with patho-
logic stage I/II/III disease were 32/7/12, respectively. With
respect to smoking index (SI), 23 patients (45.1%) were
heavy smokers (SI  600).
Of the 41 squamous cell carcinoma patients, the mean
age was 67.2 years (range 44–78 years), and there were 34
male and 7 female patients. The total numbers of patients
with pathologic stage I/II/III disease were 17/8/16, respec-
tively. With respect to SI, 37 patients (90.2%) were heavy
smokers (SI  600).
Comparison of the groups with adenocarcinoma and
squamous cell carcinoma showed that the proportion of males
and the proportion of heavy smokers were significantly
higher in squamous cell carcinoma patients than in adenocar-
cinoma patients (p  0.0025 and p  0.001, respectively).
Patients with squamous cell carcinoma tended to have more
advanced disease than did patients with adenocarcinoma, but
the difference was not statistically significant (p  0.1229).
Immunohistochemical Staining for Neuronatin
First, we confirmed the specificity of the antibody used
in this study. We detected a single immunoreactive band
corresponding to neuronatin- with an estimated molecular
mass of 9 kD in an adenocarcinoma case that showed positive
reaction by immunohistochemical staining (Figure 1).
Figure 2 shows light microscopic findings of neurona-
tin-positive cases. Positive cells were focally or diffusely
distributed in the tumor. Neuronatin was detected in the
cytoplasm, showing granular or reticular patterns, in both
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adenocarcinoma and squamous cell carcinoma. In most cases,
nontumorous lung tissue did not show positive staining.
Nevertheless, in some cases positive staining was observed to
various degrees in macrophages, normal alveolar cells, or the
nuclei of interstitial cells.
Comparison of Patient Background and
Immunohistochemical Staining
Table 1 summarizes the associations between immuno-
histochemical results and the clinicopathological features of
the patients examined. The frequency of neuronatin expres-
sion in tumor samples was significantly higher in males than
in females, higher in SI  600 than in SI  600, and higher
in squamous cell carcinoma than in adenocarcinoma. With
respect to patient age and stage of disease, we found no
significant differences between neuronatin-positive cases and
negative cases.
For adenocarcinoma, neuronatin positivity was ob-
served more frequently in less-differentiated adenocarcinoma
than in differentiated adenocarcinoma (Table 2).
For squamous cell carcinoma, we did not detect any
significant differences between neuronatin-positive cases and
neuronatin-negative cases with respect to gender, SI, stage of
disease, and histological differentiation (Table 3).
Impact of Neuronatin Expression on Survival
In an attempt to evaluate the impact of neuronatin
expression on survival, we analyzed overall survival for
patients with adenocarcinoma and squamous cell carcinoma
with respect to the results of immunohistochemical staining
for neuronatin, gender, and histological differentiation. There
were 11 deaths among the adenocarcinoma patients in the
study, and 10 of them were lung carcinoma-related. On the
other hand, there were 11 deaths among the squamous cell
carcinoma patients, and seven of them were lung carcinoma–
FIGURE 1. Western blot analysis of neuronatin (arrow) in
lung carcinoma tissue (a case of adenocarcinoma which
showed a distinct positive reaction in immunohistochemical
staining for neuronatin). kD, kilodaltons.
FIGURE 2. Light microscopic find-
ings of immunohistochemical stain-
ing for neuronatin (200). Positive
cases of adenocarcinoma (A) and
squamous cell carcinoma (B).
TABLE 1. Results of Immunohistochemical Staining for
Neuronatin in All Patients
Neuronatin Protein
Expression
Positive
(positive rate) Negative p
Total number of patients 39 53
Mean age (yr) 67.0 64.2
Gender
Male 33 (54%) 28 0.0014
Female 6 (19%) 25
Smoking index*
600 7 (22%) 25 0.029
600 32 (54%) 27
Histology
Ad 13 (25%) 38 0.001
Sq 26 (63%) 15
Pathologic stage
I 18 (37%) 31 NS
II 7 (47%) 8
III 14 (50%) 14
Ad, adenocarcinoma; Sq, squamous cell carcinoma; NS, not significant. Smoking
index  (number of cigarettes smoked/day)  (years smoked). Pathologic stage: I (IA
and IB), II (IIA and IIB), III (IIIA and IIIB). *Data not available only in one patient.
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related. As a result, the total number of cases for which
follow-up was possible for 5 years was 38 (74.5%) in ade-
nocarcinoma and 29 (70.7%) in squamous cell carcinoma.
First, we found no significant difference in overall
patient outcome between adenocarcinoma and squamous cell
carcinoma (p  0.5552, 5-year survival rates 0.753 versus
0.670).
For adenocarcinoma, as Figure 3A shows, the outcome
of patients with neuronatin-positive tumors was significantly
worse than that of patients with neuronatin-negative tumors
(p  0.0025, 5-year survival rates 0.407 versus 0.852).
Especially as Figure 3B shows, about stage I adenocarcinoma
TABLE 2. Results of Immunohistochemical Staining for
Neuronatin in Adenocarcinoma
Neuronatin Protein
Expression
Positive
(positive rate) Negative p
Total number of
patients
13 (25%) 38
Mean age (yr) 66.3 63.2
Gender NS (p  0.584)
Male 10 (37%) 17
Female 3 (13%) 21
Smoking index* NS (p  0.1386)
600 5 (18%) 23
600 8 (36%) 14
Pathologic stage NS (p  0.3110)
I 7 (22%) 25
II 1 (14%) 6
III 5 (42%) 7
Differentiation 0.0027*
Well 1 (6%) 17
Moderately 6 (25%) 18
Poorly 6 (67%) 3
NS, not significant. Smoking index  (number of cigarettes smoked/day)  (years
smoked). Pathologic stage: I (IA and IB), II (IIA and IIB), III (IIIA and IIIB). *p 
0.2080 for well versus moderately; p  0.0441 for moderately versus poorly; p 
0.0017 for well versus poorly.
TABLE 3. Results of Immunohistochemical Staining for
Neuronatin in Squamous Cell Carcinoma
Neuronatin Protein
Expression
Positive
(positive rate) Negative p
Total number of
patients
26 (63%) 15
Mean age (yr) 67.3 66.9
Gender NS (p  0.2150)
Male 23 (68%) 11
Female 3 (43%) 4
Smoking index NS (p  0.4511)
599 2 (50%) 2
600–1199 12 (75%) 4
1200 12 (57%) 9
Pathologic stage NS (p  0.6607)
I 11 (65%) 6
II 6 (75%) 2
III 9 (56%) 7
Differentiation NS (p  0.1870)
Well 1 (25%) 3
Moderately 18 (64%) 10
Poorly 7 (78%) 2
NS, not significant. Smoking index  (number of cigarettes smoked/day)  (years
smoked). Pathologic stage: I (IA and IB), II (IIA and IIB), III (IIIA and IIIB).
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FIGURE 3. Association between neuronatin expression and
survival. Overall survival for adenocarcinoma (A), stage I ade-
nocarcinoma (B), and squamous cell carcinoma (C) classified
by immunohistochemical staining for neuronatin.
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cases (32 cases), overall survival rate of neuronatin positive
cases is significantly lower than those of negative cases (p 
0.0131). Nevertheless, in stage II and III cases, there is no
significant difference of overall survival between positive and
negative cases. Male patients had significantly worse treat-
ment outcomes than did female patients (p  0.0194, 5-year
survival rates 0.617 versus 0.908). Furthermore, patients with
poorly differentiated adenocarcinoma had significantly worse
outcomes than did patients with well- or moderately differ-
entiated adenocarcinoma (p  0.0050 and 0.0266).
For squamous cell carcinoma, as Figure 3C shows, no
significant difference was observed between the survival
curves of patients with neuronatin-positive tumors and neu-
ronatin-negative tumors (p  0.9880, 5-year survival rates
0.657 versus 0.688). In addition, there were no significant
differences in outcome with respect to gender or histological
differentiation.
DISCUSSION
The neuronatin gene is generally thought to be ex-
pressed only in the pituitary gland in normal adults.6,7 Nev-
ertheless, it was recently reported that neuronatin is expressed
in pancreatic -cells17 and hematopoietic progenitor cells.18
Furthermore, RNA analysis has demonstrated neuronatin ex-
pression in some types of tumors.8,9,10
As we reported previously, neuronatin is a unique gene
that is highly expressed in large cell neuroendocrine carcino-
mas relative to small cell carcinomas of the lung.14 There was
only an imperfect correlation between neuronatin expression
and the expressions of neuroendocrine markers such as
CD56, chromogranin A, and synaptophysin among large-cell
neuroendocrine carcinomas and small cell carcinomas. From
these results, we postulated that neuronatin is not a specific
marker of neuroendocrine differentiation but rather a marker
for immature characteristics of large cell neuroendocrine
carcinomas and small-cell carcinomas. We need more exten-
sive comparative study between neuronatin expression and
other NE markers in non-small cell carcinomas of the lung to
conclude the biological meaning of neuronatin expression. In
the present study, we examined neuronatin expression in
squamous cell carcinomas and adenocarcinomas, the two
common histological subtypes of lung carcinoma, and
showed that neuronatin is expressed in both histological
subtypes. Interestingly, neuronatin expression was signifi-
cantly associated with poor prognosis of adenocarcinoma but
not of squamous cell carcinoma. Although neuronatin is
specifically expressed in the fetal nervous system in the
course of brain development, it is not thought to be a
neuroendocrine marker but, rather, an embryonal marker,
except in the pituitary gland. Several reports of characteristic
expression of neuronatin in some undifferentiated malignant
tumors, such as liposarcoma and Wilms’ tumors, support this
speculation.8,9
This study provided little information about the func-
tions of neuronatin. In adenocarcinoma, neuronatin-positive
cases had significantly worse outcomes than did neuronatin-
negative cases. The reason for this is unknown, but may be
related to the fact that neuronatin tends to be expressed in
undifferentiated carcinoma. In addition, other factors may
affect this association, such as smoking or gender. There is a
report that expression of neuronatin is related to resistance to
toxins that disturb cationic gradients.19 On the other hand,
there is an early and marked increase in neuronatin expres-
sion when a thyroid-stimulating hormone–producing tumor is
caused to regress by administration of thyroid hormone.12
Furthermore, neuronatin expression is enhanced in a mam-
mary tumor cell line that has acquired resistance to tamoxifen
(an antiestrogen hormone agent).13 These observations sug-
gest that neuronatin may be involved in the regulation of cell
growth by hormones.
This study suggests the possibility of using neuronatin
expression as a tumor marker and prognostic marker. As
neuronatin is primarily an embryonal protein, we envisage
using it as a serum marker to detect lung carcinomas. Nev-
ertheless, the antineuronatin antibody used here has not been
widely used for detection of neuronatin protein from the
serum. Furthermore, we could not prepare an authentic pos-
itive control of neuronatin protein expression. Validation of
the use of neuronatin as a tumor marker will require inves-
tigation of the tissue specificity and tumor specificity of this
antibody.
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